Advancing targeted therapies for those who need them most
From Research to Patient Impact. The Future of Oncology and Obesity Therapies
Our pipeline reflects our unwavering commitment to developing treatments for serious diseases with scientific rigor and compassion. Focused on oncology and obesity, we are advancing two key investigational therapies designed to address significant unmet medical needs.
Pipeline
CRB-701
Nectin-4 expressing solid tumors
Sponsor: CSPC (China)
Milestones: Phase 3 in cervical cancer
Sponsor: Corbus (US, Europe)
Milestones: Dose optimization in HNSCC, cervical & mUC
(FDA Fast Track Designation granted HNSCC and Cervical
CRB-913
Obesity and related conditions
Sponsor: Corbus
Milestones: 12-week dose-range study in obesity (n=240) in mid-2026
Our Oncology Pipeline
At the forefront of our oncology pipeline is a focused effort to develop science-driven treatments that engage the immune system to target cancer at its root. Grounded in advanced integrin and TGFβ biology, our research reflects both a deep understanding of the tumor microenvironment and a commitment to improving patient outcomes. Each program is designed with scientific precision and a clear objective: to unlock new pathways in cancer immunotherapy while adhering to the rigorous standards of modern drug development.
CRB-701: Precision Antibody-Drug Conjugate Cancer Treatment
CRB-701 is an antibody-drug conjugate (ADC) targeting Nectin-4, a protein expressed on certain cancer cells. This therapy is designed to deliver a cytotoxic agent directly to tumor cells, aiming to enhance treatment efficacy while minimizing impact on healthy tissues. CRB-701 is currently under investigation in clinical trials for patients with advanced solid tumors associated with high Nectin-4 expression.
Our Obesity Therapy Pipeline
Our obesity and metabolic disease clinical development is focused on scientifically validated mechanisms that regulate appetite, energy use, and metabolic function. We are advancing a next-generation therapeutic approach aimed at improving weight-related outcomes through peripheral CB1 receptor modulation. This program reflects our commitment to meticulous, science-based development, insightful design, and addressing the complex drivers of obesity with the goal of improving long-term patient health.
CRB-913: CB1R Inverse Agonist Obesity Treatment
CRB-913 is a second-generation, peripherally restricted cannabinoid receptor type 1 (CB1) inverse agonist in development for the treatment of obesity. Designed to act on peripheral CB1 receptors without affecting those in the central nervous system, CRB-913 aims to reduce food intake and promote weight loss while minimizing central side effects. Preclinical models have demonstrated significant weight loss and improvements in metabolic parameters. A Phase 1 clinical study has been initiated to evaluate its safety and efficacy in humans.
Commitment to Transparency and Collaboration
We are dedicated to maintaining transparency in our research and development efforts. Detailed information about our clinical trials, including eligibility criteria and enrollment status, is available at Our Trials. At Corbus we encourage healthcare professionals, patients, and stakeholders to explore these resources directly for further information about our ongoing studies.